Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company. South San Francisco, California, United States 251-500

This website uses cookies and similar technologies to optimise and improve the experience on our site. By continuing to use this website, you agree to the use of

Drill Template Guide Drilling Jig For Knobs Cabinet Drawer Black & Decker CD301 manual. Gradskiva - Geometri Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics, Inc. has a P/E ratio of 0, compared to Amgen Inc’s 20.75 and Bristol-Myers Squibb Company’s 0. Also in last trading session, the S&P 500 Index has surged 0.18%, while the Dow Jones Industrial also saw a negative seesion, down -0.18% on the day.

Atara biotherapeutics

Eric Hyllengren - VP, IR & Finance. Pascal Touchon - President and CEO Atara Biotherapeutics IPO’d in 2014 and is a San Francisco, California-based clinical-stage biotechnology company.Atara is a leading off-the-shelf, allogenic T-cell immunotherapy company focused 2021-02-08 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases 2021-03-05 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transfor Role model for Atara’s Values of patients first, innovation teamwork, community and mindset. We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options. We’re named after Atara Ciechanover who suffered from cancer before passing away. 2021-01-04 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options. We are considered a leading off-the-shelf T-cell immunotherapy company (Nasdaq ATRA) developing novel treatments for patients with cancer, autoimmune and viral diseases.

Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, Atara Biotherapeutics Inc. (NASDAQ:ATRA) went up by 0.65% from its latest closing price compared to the recent 1-year high of $28.20.

About Atara Biotherapeutics Inc. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for

Atara Biotherapeutics has received 55.69% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Atara Biotherapeutics is a Tier 4 development firm based out of San Francisco.

Role model for Atara TRAIT values (Transparency, Respect, Accountability, Integrity, Trust) More About Atara Bio We launched Atara Biotherapeutics in August 2012 to help patients with serious

november 2014 – juli 2016 1 år 9 månader. South San Francisco, CA. Bild för Manager, Partner and Office Affairs Atara Biotherapeutics är en aktie med ISIN-kod US0465131078, listad som ATRA på Nasdaq Stock Exchange. Ledande sponsor: Atara Biotherapeutics. Källa, Atara Biotherapeutics. Kort sammanfattning. Det primära målet med detta protokoll är att ge utökad tillgång till 23, 19, ATARA BIOTHERAPEUTICS, US0465131078, United States, USD, NASDAQ National Market System, Equity, -, NASDAQ Composite Index, Health Care Atara Biotherapeutics and Exelixis might be top takeover targets for the biotech giant. Atara Biotherapeutics, Inc. ATGN Consulting Athenion AG ATIcure AG AUM Biosciences Aurealis Therapeutics AG Avectas Ltd. B3C Group Global X SuperDividend Alternatives ETF, Atara Biotherapeutics, Inc. Delek Logistics Partners,.

The shares were sold at an average price of $14.58, for a total transaction of $38,491.20. Following the completion of the sale, the insider now directly owns 135,579 shares of the company’s stock, […] Убыток Atara Biotherapeutics по GAAP за 6 мес. 2020 г.
Kärnhuset kivik dagens

Source: Bayer and Atara Biotherapeutics, Inc. Released December 6, 2020 Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021 Feb 18, 2021 4:01pm EST Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Role model for Atara TRAIT values (Transparency, Respect, Accountability, Integrity, Trust) More About Atara Bio We launched Atara Biotherapeutics in August 2012 to help patients with serious Role model for Atara TRAIT values (Transparency, Respect, Accountability, Integrity, Trust) We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options. We’re named after Atara Ciechanover who suffered from cancer before passing away. We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options.

$8.6B. $1.2B.
Allra tandvardsforsakring skadeblankett

Atara Biotherapeutics, Inc. http://www.atarabio.com/. Already a Biomedtracker subscriber? You have access to the full company record through your subscription

Ireland och. 2.

Lidingö stad pernilla

Global X SuperDividend Alternatives ETF, Atara Biotherapeutics, Inc. Delek Logistics Partners,. Common Units representing Limited Partner

More Details. Rewards. Trading at 26.9% below our estimate of its fair value. Risk Analysis. 2021-4-2 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases.